Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study

Aposcience AG received the Recommendations of the Data Safety Monitoring Board (DSMB).

On 30 July 2021, three experts in the field of wound healing, after revising the data of the Lead In-Phase of the MARSYAS II trial (EudraCT No. 2018-001653-27), decided unanimously that the investigational medicinal product APO-2 is safe for patients and recommended to continue with the main phase of the trial without amendments.